Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2000 Mar;68(3):313–316. doi: 10.1136/jnnp.68.3.313

Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism

B Snow 1, F Vingerhoets 1, J Langston 1, J Tetrud 1, V Sossi 1, D Calne 1
PMCID: PMC1736814  PMID: 10675212

Abstract

OBJECTIVES—To examine the distribution of striatal dopaminergic function in humans with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to determine if there is a caudate-putamen gradient as is seen in idiopathic Parkinson's disease.
METHODS—We scanned nine humans exposed to MPTP with parkinsonism ranging from minimal to severe using [18F]fluorodopa (FD) and high resolution PET. The results were compared with those of 10 patients with Parkinson's disease and six normal subjects.
RESULTS—In the MPTP group there was an equal degree of reduction of dopaminergic function in the caudate and putamen. This was different from the greater putaminal than caudate loss in Parkinson's disease (p<0.001).
CONCLUSIONS—Parkinson's disease is not caused by transient exposure to MPTP.



Full Text

The Full Text of this article is available as a PDF (139.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander G. M., Schwartzman R. J., Brainard L., Gordon S. W., Grothusen J. R. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys. Brain Res. 1992 Aug 21;588(2):261–269. doi: 10.1016/0006-8993(92)91584-2. [DOI] [PubMed] [Google Scholar]
  2. Bailey D. L., Meikle S. R. A convolution-subtraction scatter correction method for 3D PET. Phys Med Biol. 1994 Mar;39(3):411–424. doi: 10.1088/0031-9155/39/3/009. [DOI] [PubMed] [Google Scholar]
  3. Brooks D. J., Ibanez V., Sawle G. V., Quinn N., Lees A. J., Mathias C. J., Bannister R., Marsden C. D., Frackowiak R. S. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol. 1990 Oct;28(4):547–555. doi: 10.1002/ana.410280412. [DOI] [PubMed] [Google Scholar]
  4. Burn D. J., Sawle G. V., Brooks D. J. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry. 1994 Mar;57(3):278–284. doi: 10.1136/jnnp.57.3.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Burns R. S., Chiueh C. C., Markey S. P., Ebert M. H., Jacobowitz D. M., Kopin I. J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A. 1983 Jul;80(14):4546–4550. doi: 10.1073/pnas.80.14.4546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Calne D. B., Langston J. W., Martin W. R., Stoessl A. J., Ruth T. J., Adam M. J., Pate B. D., Schulzer M. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature. 1985 Sep 19;317(6034):246–248. doi: 10.1038/317246a0. [DOI] [PubMed] [Google Scholar]
  7. Cherry S. R., Dahlbom M., Hoffman E. J. 3D PET using a conventional multislice tomograph without septa. J Comput Assist Tomogr. 1991 Jul-Aug;15(4):655–668. doi: 10.1097/00004728-199107000-00023. [DOI] [PubMed] [Google Scholar]
  8. Elsworth J. D., Deutch A. Y., Redmond D. E., Jr, Sladek J. R., Jr, Roth R. H. MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys. Brain Res. 1990 Apr 16;513(2):320–324. doi: 10.1016/0006-8993(90)90474-p. [DOI] [PubMed] [Google Scholar]
  9. Elsworth J. D., Deutch A. Y., Redmond D. E., Jr, Taylor J. R., Sladek J. R., Jr, Roth R. H. Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates: biochemical changes in striatal regions. Neuroscience. 1989;33(2):323–331. doi: 10.1016/0306-4522(89)90212-1. [DOI] [PubMed] [Google Scholar]
  10. Forno L. S., DeLanney L. E., Irwin I., Langston J. W. Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations. Adv Neurol. 1993;60:600–608. [PubMed] [Google Scholar]
  11. Garnett E. S., Nahmias C., Firnau G. Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography. Can J Neurol Sci. 1984 Feb;11(1 Suppl):174–179. doi: 10.1017/s0317167100046369. [DOI] [PubMed] [Google Scholar]
  12. German D. C., Dubach M., Askari S., Speciale S. G., Bowden D. M. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost? Neuroscience. 1988 Jan;24(1):161–174. doi: 10.1016/0306-4522(88)90320-x. [DOI] [PubMed] [Google Scholar]
  13. German D. C., Manaye K., Smith W. K., Woodward D. J., Saper C. B. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann Neurol. 1989 Oct;26(4):507–514. doi: 10.1002/ana.410260403. [DOI] [PubMed] [Google Scholar]
  14. Gibb W. R., Lees A. J. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1991 May;54(5):388–396. doi: 10.1136/jnnp.54.5.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gibb W. R. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res. 1992 May 29;581(2):283–291. doi: 10.1016/0006-8993(92)90719-p. [DOI] [PubMed] [Google Scholar]
  16. Hantraye P., Varastet M., Peschanski M., Riche D., Cesaro P., Willer J. C., Maziere M. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neuroscience. 1993 Mar;53(1):169–178. doi: 10.1016/0306-4522(93)90295-q. [DOI] [PubMed] [Google Scholar]
  17. Hirsch E. C. Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease? Ann Neurol. 1992;32 (Suppl):S88–S93. doi: 10.1002/ana.410320715. [DOI] [PubMed] [Google Scholar]
  18. Hirsch E., Graybiel A. M., Agid Y. A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature. 1988 Jul 28;334(6180):345–348. doi: 10.1038/334345a0. [DOI] [PubMed] [Google Scholar]
  19. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  20. Irwin I., DeLanney L. E., Forno L. S., Finnegan K. T., Di Monte D. A., Langston J. W. The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey. Brain Res. 1990 Oct 29;531(1-2):242–252. doi: 10.1016/0006-8993(90)90780-f. [DOI] [PubMed] [Google Scholar]
  21. Kish S. J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med. 1988 Apr 7;318(14):876–880. doi: 10.1056/NEJM198804073181402. [DOI] [PubMed] [Google Scholar]
  22. Langston J. W., Ballard P., Tetrud J. W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983 Feb 25;219(4587):979–980. doi: 10.1126/science.6823561. [DOI] [PubMed] [Google Scholar]
  23. Marshall J. F., Navarrete R. J. Contrasting tissue factors predict heterogeneous striatal dopamine neurotoxicity after MPTP or methamphetamine treatment. Brain Res. 1990 Nov 26;534(1-2):348–351. doi: 10.1016/0006-8993(90)90156-6. [DOI] [PubMed] [Google Scholar]
  24. Moratalla R., Quinn B., DeLanney L. E., Irwin I., Langston J. W., Graybiel A. M. Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A. 1992 May 1;89(9):3859–3863. doi: 10.1073/pnas.89.9.3859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Pifl C., Schingnitz G., Hornykiewicz O. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience. 1991;44(3):591–605. doi: 10.1016/0306-4522(91)90080-8. [DOI] [PubMed] [Google Scholar]
  26. Pifl C., Schingnitz G., Hornykiewicz O. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease. Neurosci Lett. 1988 Oct 5;92(2):228–233. doi: 10.1016/0304-3940(88)90066-3. [DOI] [PubMed] [Google Scholar]
  27. Pérez-Otaño I., Oset C., Luquin M. R., Herrero M. T., Obeso J. A., Del Río J. MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration. Neurosci Lett. 1994 Jul 4;175(1-2):121–125. doi: 10.1016/0304-3940(94)91094-4. [DOI] [PubMed] [Google Scholar]
  28. Sawle G. V., Brooks D. J., Marsden C. D., Frackowiak R. S. Corticobasal degeneration. A unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain. 1991 Feb;114(Pt 1B):541–556. doi: 10.1093/brain/114.1.541. [DOI] [PubMed] [Google Scholar]
  29. Spokes E. G., Bannister R., Oppenheimer D. R. Multiple system atrophy with autonomic failure: clinical, histological and neurochemical observations on four cases. J Neurol Sci. 1979 Sep;43(1):59–82. doi: 10.1016/0022-510x(79)90073-x. [DOI] [PubMed] [Google Scholar]
  30. Stern Y., Tetrud J. W., Martin W. R., Kutner S. J., Langston J. W. Cognitive change following MPTP exposure. Neurology. 1990 Feb;40(2):261–264. doi: 10.1212/wnl.40.2.261. [DOI] [PubMed] [Google Scholar]
  31. Turjanski N., Lees A. J., Brooks D. J. Dopaminergic function in patients with posttraumatic parkinsonism: an 18F-dopa PET study. Neurology. 1997 Jul;49(1):183–189. doi: 10.1212/wnl.49.1.183. [DOI] [PubMed] [Google Scholar]
  32. Vingerhoets F. J., Snow B. J., Schulzer M., Morrison S., Ruth T. J., Holden J. E., Cooper S., Calne D. B. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J Nucl Med. 1994 Jan;35(1):18–24. [PubMed] [Google Scholar]
  33. Vingerhoets F. J., Snow B. J., Tetrud J. W., Langston J. W., Schulzer M., Calne D. B. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol. 1994 Nov;36(5):765–770. doi: 10.1002/ana.410360513. [DOI] [PubMed] [Google Scholar]
  34. Yamada T., McGeer P. L., Baimbridge K. G., McGeer E. G. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res. 1990 Sep 3;526(2):303–307. doi: 10.1016/0006-8993(90)91236-a. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES